Oncology Nutrition Market to reach USD 5.58 Billion by 2035 at 6.55% CAGR

Oncology Nutrition Market to Surge from USD 2.96 Billion in 2025 to USD 5.58 Billion by 2035- Rising Cancer Prevalence, Guideline-Mandated Nutrition Screening

NY, CA, UNITED STATES, September 7, 2026 /EINPresswire.com/ -- As per Market Research Future, the global Oncology Nutrition Market size is projected to reach USD 5.58 Billion by 2035 from USD 2.96 Billion in 2025, at a CAGR of 6.55% during the forecast period 2025--2035. The market base was estimated at USD 2.96 Billion in 2025.

The 6.55% CAGR---anchored by structural shifts in cancer care management---is propelled by three converging forces: the rising global prevalence of cancer, with GLOBOCAN projecting regional incidence growth at roughly 2.1% annually through 2035, driving healthcare providers to increasingly adopt oncology nutrition protocols for superior patient outcomes, reduced treatment interruptions, and long-term recovery support; advancements in nutrition formulations, particularly immunonutrition and disease-specific products enriched with omega-3, high-leucine, and low-osmolality elemental lines, which significantly improve patient adherence and clinical efficacy; and the expansion of reimbursement pathways, including Medicare Part B coverage criteria for home enteral feeding and ESPEN's updated clinical practice guidelines, that enhance patient access and convert nutrition support from discretionary purchase to protocol line item.

Global pharmaceutical and nutrition companies are amplifying this momentum. Abbott Laboratories holds an estimated 17--21% revenue share in the oncology nutrition space, reflecting strong investment in clinical nutrition portfolios. Nestlé Health Science commands approximately 15--19% of the market, supporting development of peptide-based and immunomodulating formulas. According to GLOBOCAN data, gastric and oesophageal tumours---both high-risk for cachexia---are over-represented in Asia-Pacific versus Western profiles. ESPEN audited European centers implementing upstream nutrition screening reported a 21% reduction in unexpected treatment interruptions. These forces are creating the clinical infrastructure and patient demand on which the Oncology Nutrition Market depends.

Request A Free Sample:

https://www.marketresearchfuture.com/sample_request/34133

Key Market Trends & Growth Drivers

Rising Demand for Cancer-Specific Nutrition Solutions

The market is witnessing an increasing demand for nutrition products tailored to cancer patients. As cancer rates continue to rise globally, more individuals require effective nutritional interventions to manage cachexia, mucositis, and treatment-related weight loss. This trend indicates a shift in clinical attitudes towards proactive nutrition management, with oncology nutrition products being recognized for their dual benefits of sustaining body composition and supporting treatment tolerance. Nestlé Health Science continues advancing product development through peptide-based oncology feeding ranges while strengthening clinical evidence generation.

Advancements in Immunonutrition Formulations

Innovations in nutrition formulations are becoming a hallmark of the industry. Manufacturers are exploring various product lines, including immunonutrition formulas enriched with arginine, omega-3 fatty acids, and nucleotides, as well as disease-specific and elemental formulations. These advancements aim to enhance patient compliance and clinical outcomes, potentially leading to better health results and increased market penetration. Immunonutrition formulations accounted for approximately 8.37% CAGR growth, driven by perioperative outcome evidence and 40--60% price premiums where surgical societies have written them into pathways.

Integration of Digital Health and Connected Feeding

The incorporation of digital health technologies into the industry is gaining traction. Tools such as connected feeding pumps with telemetry modules and mobile applications for intake logging are being utilized to monitor patient progress and facilitate communication between healthcare providers and patients. Abbott continues investing in connected diabetes care and partnered with a US home-infusion network to bundle connected feeding pumps with consumable subscriptions, generating longitudinal adherence datasets.

Increasing Prevalence of Cancer and Malnutrition

The rising incidence of cancer and associated malnutrition is a primary driver. According to GLOBOCAN, cancer incidence is projected to grow at roughly 2.1% annually through 2035, with over 830 million people worldwide affected by chronic disease conditions. The market is projected to expand as healthcare providers increasingly prescribe oncology nutrition products to manage chronic conditions. The World Health Organization has identified cancer as a leading cause of mortality worldwide, underscoring the urgent need for innovative nutritional solutions.

Ask for Customization:

https://www.marketresearchfuture.com/ask_for_customize/34133

Market Segment Insights

BY FORMULA TYPE

Standard Formula: Largest segment with **48.3% share in 2025**, driven by cost efficiency, tender defaults, and broad tolerance across patient populations. Abbott continues expanding standard formula distribution through hospital formulary partnerships.

Disease-Specific Formula: Significant share at **USD 0.63 Billion**, catering to patients with diabetes, renal, and hepatic comorbidities requiring tailored macronutrient profiles.

Immunonutrition Formula: Fastest-growing segment at **8.37% CAGR**, appealing to surgical and perioperative oncology programmes seeking evidence-based outcome improvements.

Elemental / Semi-Elemental: Positioned for severe malabsorption and mucositis cases, accounting for **10.2% share in 2025**.

BY NUTRITION TYPE

Enteral Nutrition: Dominant route with **70.3% share in 2025**, reflecting clinical guideline preference for using the gut when functional. Danone continues expanding enteral nutrition portfolios through disease-specific and high-energy compact lines.

Parenteral Nutrition: Fastest-growing type at **7.12% CAGR**, tracking gut-failure and short-bowel caseloads as complex GI surgical volumes rise.

BY CANCER TYPE

Head & Neck Cancer: Largest segment with **30.5% share in 2025**, sustained by prolonged dysphagia and xerostomia feeding windows that can render oral intake impossible for months.

Lung Cancer: Fastest-growing indication at **7.76% CAGR**, as immunotherapy-led regimens raise metabolic demand and extend survival, generating more cumulative product per patient.

Stomach & Gastrointestinal Cancers: Significant share at **USD 0.59 Billion**, driven by malabsorption and post-gastrectomy nutritional needs.

Breast Cancer: Smaller but established share at **12.6%**, reflecting treatment-related weight fluctuation management.

BY END USER

Hospitals: Largest segment, generating **USD 1.84 Billion in 2025** across inpatient, surgical, and infusion-suite settings. Fresenius Kabi continues strengthening hospital pharmacy presence through integrated device-plus-nutrient offerings.

Home Care: Fastest-growing end user at **9.01% CAGR**, reflecting reimbursed discharge pathways and payer savings from moving feeding out of acute beds.

Specialty Oncology Clinics: Significant share at **13.6% in 2025**, due to network formulary consolidation and centralized purchasing across regional clinic networks.

BY DISTRIBUTION CHANNEL

Hospital Pharmacies: Largest segment, benefiting from direct access to inpatients and infusion-suite settings requiring specialized nutritional support.

Retail Pharmacies: Significant share, driven by outpatient prescriptions and home care continuity as patients transition from acute to community settings.

Online Pharmacies: Fastest-growing channel, gaining traction among tech-savvy consumers and caregivers seeking convenience and subscription-based replenishment.

Read Detailed Insights:

https://www.marketresearchfuture.com/reports/oncology-nutrition-market-34133

Regional Outlook

North America --- Market Leader in Innovation

North America leads with 41.8% of global revenue in 2025, generating around USD 1.24 Billion. The region's growth is driven by increasing cancer prevalence, rising healthcare expenditure, and favorable reimbursement policies. According to CMS data, the 2023 expansion of Medicare Part B coverage criteria for home enteral feeding removed documentation barriers that had stranded thousands of post-surgical head-and-neck patients. Hospital readmission penalties under the Hospital Readmissions Reduction Program gave discharge planners a financial reason to fund post-acute nutrition. The competitive landscape is characterized by continuous innovation and strategic partnerships among leading nutrition companies.

Europe --- Second Largest Market

Europe was valued at USD 0.78 billion in 2025, representing the second-largest regional market. The region benefits from increasing awareness of cancer nutrition management and supportive healthcare policies. Regulatory bodies like the EMA and national HTA bodies are actively facilitating the approval of new therapies and evaluating nutrition support against avoided bed-days rather than food cost. Leading countries include Germany, the UK, and France, where major companies such as Danone (Nutricia) and Fresenius Kabi are heavily invested. NICE updated malnutrition pathway guidance in January 2025 to strengthen screening frequency recommendations across cancer treatment cycles.

Asia-Pacific --- Rapidly Growing Market Segment

The Asia-Pacific region accounts for a significant share of the global market and is compounding at 7.62% CAGR. The growth is driven by rising cancer rates, urbanization, and increasing healthcare access. Countries like China and India are experiencing a surge in demand, supported by government initiatives such as China's National Cancer Prevention Action Plan and India's Ayushman Bharat oncology packages. The competitive landscape is evolving with companies like Otsuka Pharmaceutical and Meiji Holdings leading the charge, while local manufacturing becomes table stakes due to import duties and registration timelines.

South America --- Emerging Opportunity

South America holds around 5.6% of the global share, driven by expanding private insurance coverage and retail pharmacy networks. Brazil's supplementary health regulator has progressively widened mandated coverage lists, and hospital groups in São Paulo and Rio now run dedicated nutrition teams comparable to European tertiary centres. Public-sector penetration remains shallow outside capital cities, presenting untapped potential for market expansion.

Middle East and Africa --- Untapped Potential

The MEA region was valued at USD 0.13 Billion in 2025, driven by increasing awareness of cancer and malnutrition, coupled with rising healthcare investments. Countries like Saudi Arabia, the UAE, and South Africa are leading the way, with a growing presence of international nutrition companies. Gulf states buy through large centralised tenders, rewarding suppliers with regional registration and warehousing. Sub-Saharan demand is constrained by out-of-pocket financing, with donor-funded oncology programmes remaining the practical entry route.

Competitive Landscape and Recent Developments

The oncology nutrition market is characterized by moderate concentration and rapid growth, driven by increasing prevalence of cancer worldwide. The global industry appears moderately consolidated, with the top five suppliers holding an estimated 61--66% of global revenue, producing an HHI in the 1,050--1,300 range. Scale in clinical evidence generation and hospital contracting, not manufacturing cost, is the real barrier to entry.

KEY COMPANIES AND RECENT MILESTONES

Abbott Laboratories (US): Holds an estimated **17--21% revenue share** in the oncology nutrition space. Continues advancing oral supplements and tube-feed polymeric lines through retail plus hospital dual-channel scale. Partnered with a US home-infusion network in September 2024 to bundle connected feeding pumps with consumable subscriptions.

Nestlé Health Science (CH): Commands approximately **15--19%** of the market. Continues advancing peptide-based and immunomodulating formulas through clinical evidence and acquisition-led breadth. Expanded its peptide-based oncology feeding range across EU markets in March 2023, targeting mucositis-limited patients who fail standard polymeric tolerance.

Danone (Nutricia) (FR): Holds approximately **12--15%** market share. Launched a plant-protein oncology supplement line in Western Europe in April 2024, responding to taste-aversion and sustainability procurement criteria. Maintains the strongest European formulary access through disease-specific and high-energy compact lines.

Fresenius Kabi (DE): Holds approximately **9--12%** market share. Commissioned additional multi-chamber parenteral bag capacity in Europe in November 2023 to address supply constraints in oncology infusion pharmacy. Offers integrated device-plus-nutrient solutions spanning parenteral bags, lipid emulsions, and pumps.

Baxter International (US): Holds approximately **6--9%** market share. Acquired a regional compounding pharmacy platform in May 2025 to shorten parenteral delivery lead times in the Midwest. Specializes in multi-chamber parenteral systems with compounding and hospital pharmacy depth.

Other Key Players: B. Braun Melsungen (DE), Otsuka Pharmaceutical (JP), Meiji Holdings (JP), Hormel Health Labs (US), Victus Inc. (US), Global Health Products (US).

Future Outlook: 2025--2035

The Oncology Nutrition Market is projected to reach USD 5.58 billion by 2035, growing at a CAGR of 6.55%, driven by increasing cancer prevalence, rising awareness of malnutrition in oncology, and advancements in immunonutrition formulations.

New opportunities lie in:

Expansion into emerging markets with tailored, affordable nutrition formats such as sachet-based products
Development of precision nutrition therapies matched to metabolic phenotyping and body composition imaging
Investment in digital health platforms and connected feeding devices for patient engagement and adherence monitoring
Value-based nutrition contracting tied to avoided readmissions and completed chemotherapy cycles
By 2035, the Oncology Nutrition Market is expected to achieve substantial growth and innovation.

More Related Research Insights:

https://www.marketresearchfuture.com/fr/reports/health-supplements-market-1646

https://www.marketresearchfuture.com/ja/reports/health-supplements-market-1646

https://www.marketresearchfuture.com/de/reports/health-supplements-market-1646

https://www.marketresearchfuture.com/es/reports/health-supplements-market-1646

https://www.marketresearchfuture.com/zh-cn/reports/health-supplements-market-1646

https://www.marketresearchfuture.com/ko/reports/health-supplements-market-1646

https://www.marketresearchfuture.com/fr/reports/laboratory-equipment-market-8365

https://www.marketresearchfuture.com/ja/reports/laboratory-equipment-market-8365

https://www.marketresearchfuture.com/de/reports/laboratory-equipment-market-8365

https://www.marketresearchfuture.com/fr/reports/medical-second-opinion-market-9701

Market Research Future
Market Research Future
+1 855-661-4441
email us here